A Study of RO4989991 in Patients With Allergic Rhinitis

Summary

This multi-center, randomized, observer-blinded, placebo-controlled study will evaluate the safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic rhinitis who are otherwise healthy. The anticipated time on study treatment is 2 weeks.

Timeline

Start

2010-07

Primary completion

2011-02

Completion

2011-02

Drugs

Indications